Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Robert S Epstein. (2021) Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs. ClinicoEconomics and Outcomes Research 13, pages 801-807.
Read now
Read now
Francesco Patti, María Luisa Martínez Ginés, Christiane Norenberg & Fernando Duarte Caron. (2020) BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT®. Patient Preference and Adherence 14, pages 771-779.
Read now
Read now
Diana Ferraro, Valentina Camera, Eleonora Baldi, Veria Vacchiano, Erica Curti, Angelica Guareschi, Susanna Malagù, Sara Montepietra, Silvia Strumia, Mario Santangelo, Luisa Caniatti, Matteo Foschi, Alessandra Lugaresi, Franco Granella, Ilaria Pesci, Luisa Motti, Walter Neri, Paolo Immovilli, Enrico Montanari, Francesca Vitetta, Anna Maria Simone & Patrizia Sola. (2018) First-line disease-modifying drugs in relapsing–remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Current Medical Research and Opinion 34:10, pages 1803-1807.
Read now
Read now
V Limmroth, J Reischl, B Mann, X Morosov, A Kokoschka, I Weller & T Schreiner. (2017) Autoinjector preference among patients with multiple sclerosis: results from a national survey. Patient Preference and Adherence 11, pages 1325-1334.
Read now
Read now
Marieke Krol, Gert de Voer & Ulrike Osowski. (2017) Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis. Patient Preference and Adherence 11, pages 1189-1196.
Read now
Read now
Alessandra Lugaresi, Francesca De Robertis, Marinella Clerico, Vincenzo Brescia Morra, Diego Centonze, Stefano Borghesan & Giorgia Teresa Maniscalco. (2016) Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study. Expert Opinion on Drug Delivery 13:7, pages 931-935.
Read now
Read now
Danny Decoo & Mathieu Vokaer. (2015) Treatment adherence in multiple sclerosis: a survey of Belgian neurologists. Patient Preference and Adherence 9, pages 1669-1676.
Read now
Read now
Ivonne Weller, Anna Saake, Thomas Schreiner, Julika Vogelreuter & Nicolas Petroff. (2015) Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b. Patient Preference and Adherence 9, pages 951-959.
Read now
Read now
Marcello Moccia, Raffaele Palladino, Cinzia Russo, Marco Massarelli, Antonio Nardone, Maria Triassi, Alessandra Lugaresi & Vincenzo Brescia Morra. (2015) How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. Expert Opinion on Drug Delivery 12:12, pages 1829-1835.
Read now
Read now
Articles from other publishers (38)
Herbert Schreiber, Joachim Hipp, Fabian Roßnagel & Christiane Moritz. (2023) Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing–remitting multiple sclerosis patients. Neurodegenerative Disease Management.
Crossref
Crossref
Roberta Di Terlizzi, Miriam King & Christian Blohm. (2023)
Usability validation of the Sensoready
®
pen in patients with relapsing multiple sclerosis
. Therapeutic Delivery.
Crossref
Crossref
Amy Perrin Ross, Christian Besser, Shubhanvita Naval, Dee Stoneman, Harriet Gaunt & Noreen Barker. (2023) Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey. BMC Neurology 23:1.
Crossref
Crossref
Francesco Patti, Clara Grazia Chisari, Simona Toscano, Pietro Annovazzi, Paola Banfi, Roberto Bergamaschi, Raffaella Clerici, Marta Zaffira Conti, Antonio Cortese, Roberta Fantozzi, Diana Ferraro, Mariano Fischetti, Maura Frigo, Maurizia Gatto, Paolo Immovilli, Stefania Leoni, Simona Malucchi, Giorgia Maniscalco, Girolama Alessandra Marfia, Damiano Paolicelli, Paola Perini, Carlo Serrati, Rocco Totaro, Gabriella Turano, Paola Valentino, Mauro Zaffaroni, Cristina Zuliani & Diego Centonze. (2023) Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study. Multiple Sclerosis and Related Disorders 70, pages 104474.
Crossref
Crossref
Michael Lang, Lukas Cepek, Daniela Rau, Nadine Denkinger, Katja Behrens & Anselm Kornhuber. (2022) Steigerung der Therapietreue durch niederschwellige Kontakte. Nervenheilkunde 41:07/08, pages 497-501.
Crossref
Crossref
Ricardo Alonso, Juan I. Rojas, Juan Ramos, Patricio Correa, Cecilia Pita, Leila Cohen, Sandra Vanotti, Orlando Garcea & Berenice A. Silva. (2022) Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America. Multiple Sclerosis and Related Disorders 63, pages 103915.
Crossref
Crossref
Ryan Farej, Mark Rametta, Anneliese La Rose, Apryl Quillen & Kim McLeod. (2022) A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector. Neurology and Therapy 11:1, pages 373-384.
Crossref
Crossref
Francesco Patti, Javier Nicolas Penaherrera, Lorissa Zieger & Eva-Maria Wicklein. (2021) Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. BMC Neurology 21:1.
Crossref
Crossref
Anitha Roy, Royapuram Veeraragavan Geetha, Anitha Magesh, Rajagopalan Vijayaraghavan & Veerasamy Ravichandran. (2021) Autoinjector – A smart device for emergency cum personal therapy. Saudi Pharmaceutical Journal 29:10, pages 1205-1215.
Crossref
Crossref
Dylan R. Rice, Tamara B. Kaplan, Gladia C. Hotan, Andre C. Vogel, Marcelo Matiello, Rebecca L. Gillani, Spencer K. Hutto, Andrew S. Ham, Eric C. Klawiter, Ilena C. George, Kristin Galetta & Farrah J. Mateen. (2021) Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial. Journal of the Neurological Sciences 428, pages 117612.
Crossref
Crossref
Oisín Butler, Simone Heeg, Katsiaryna Holl, Ann-Kathrin Frenz, Eva-Maria Wicklein, Mark Rametta & Sandy Yeo. (2021) Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT® Autoinjector: A Retrospective Cohort Study. Drugs - Real World Outcomes 8:3, pages 359-367.
Crossref
Crossref
Ashutosh Tripathi, Carl Whitehead, Katelyn Surrao, Ananya Pillai, Amit Madeshiya, Yong Li, Hesam Khodadadi, Anthony O. Ahmed, Gustavo Turecki, Babak Baban & Anilkumar Pillai. (2021) Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway. Molecular Psychiatry 26:7, pages 3043-3059.
Crossref
Crossref
Ricardo Alonso, Orlando Garcea, María Barbara Eizaguirre, Federico Man, Abril Lopez Bizzo, Leila Cohen, Juan I Rojas, Liliana Patrucco, Edgardo Cristiano, Cecilia Pita, Veronica Tkachuk, Maria Eugenia Balbuena, Edgar Carnero Contentti, Pablo Lopez, Juan Pablo Pettinichi, Norma Deri, Jimena Miguez, Agustín Pappolla, Luciana Lazaro, Nora Fernadez Liguori, Jorge Correale, Adriana Carrá & Berenice A Silva. (2021) Usage trend of oral drugs for multiple sclerosis patients in Argentina. Multiple Sclerosis and Related Disorders 47, pages 102664.
Crossref
Crossref
L.A. Visser, C. Louapre, C.A. Uyl-de Groot & W.K. Redekop. (2020) Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 39, pages 101929.
Crossref
Crossref
Niklas Frahm, Michael Hecker & Uwe Klaus Zettl. (2019) Polypharmacy in patients with multiple sclerosis: a gender-specific analysis. Biology of Sex Differences 10:1.
Crossref
Crossref
Michael Lang, Martin Mayr, Stefan Ringbauer & Lukas Cepek. (2019) PatientConcept App: Key Characteristics, Implementation, and its Potential Benefit. Neurology and Therapy 8:1, pages 147-154.
Crossref
Crossref
Maryam Zulfiqar, Fares Qeadan, Asad Ikram, Mudassir Farooqui, Sarah P. Richardson, Christopher S. Calder, Syed A. Quadri, Puja Mathur, Corey Ford, Santiago O.Gutierrez, Enrique Liera, Harry Snow, Joel N.Gonzalez & Atif Zafar. (2019) Intracerebral Hemorrhage in Multiple Sclerosis: A Retrospective Cohort Study. Journal of Stroke and Cerebrovascular Diseases 28:2, pages 267-275.
Crossref
Crossref
E. D’Amico, A. Zanghì, M. Sciandra, G. Borriello, G. Callari, A. Gallo, G. Salemi, S. Cottone, M. Buccafusca, P. Valentino, R. B. Bossio, L. M. E. Grimaldi, C. Pozzilli, G. Tedeschi, M. Zappia & F. Patti. (2018) Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology 266:2, pages 411-416.
Crossref
Crossref
Volker Limmroth, Iason Bartzokis, Eckhard Bonmann, Patrick Kusel, Thomas Schreiner & Markus Schürks. (2018) The BETACONNECT™ system: MS therapy goes digital. Neurodegenerative Disease Management 8:6, pages 399-410.
Crossref
Crossref
Vincent Schlegel & Emmanuelle Leray. (2018) From Medical Prescription to Patient Compliance. International Journal of MS Care 20:6, pages 279-286.
Crossref
Crossref
Andrés Barboza. (2018) Suspensión de las terapias modificadoras de la enfermedad en esclerosis múltiple. Una aproximación multidimensional. Neurología Argentina 10:4, pages 232-240.
Crossref
Crossref
G. Defer, J. de Seze, S. Bouee, L. Courouve, J. Longin, M. Payet & A.S. Jean Deleglise. (2018) Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study. Multiple Sclerosis and Related Disorders 25, pages 276-281.
Crossref
Crossref
Tobias Sejbaek, Mads Nybo, Thor Petersen & Zsolt Illes. (2018) Real-life persistence and tolerability with dimethyl fumarate. Multiple Sclerosis and Related Disorders 24, pages 42-46.
Crossref
Crossref
Ingo Kleiter, Michael Lang, Judith Jeske, Christiane Norenberg, Barbara Stollfuß & Markus Schürks. (2017) Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study. BMC Neurology 17:1.
Crossref
Crossref
Frank A. Hoffmann, Anastasiya Trenova, Miguel A. Llaneza, Johannes Fischer, Giacomo Lus, Dorothea von Bredow, Núria Lara, Elaine Lam, Marlies Van Hoef & Rajesh Bakshi. (2017) Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study. BMC Neurology 17:1.
Crossref
Crossref
Simona Lattanzi, Maura Danni, Ruja Taffi, Raffaella Cerqua, Giulia Carlini, Alessandra Pulcini, Leandro Provinciali & Mauro Silvestrini. (2017) Persistence to oral disease-modifying therapies in multiple sclerosis patients. Journal of Neurology 264:11, pages 2325-2329.
Crossref
Crossref
U. K. Zettl, H. Schreiber, U. Bauer-Steinhusen, T. Glaser, K. Hechenbichler & M. Hecker. (2017) Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis. Acta Neurologica Scandinavica 136:2, pages 116-121.
Crossref
Crossref
Michel Farnier, Helen M. Colhoun, William J. Sasiela, Jay M. Edelberg, Gaëlle Asset & Jennifer G. Robinson. (2017) Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. Journal of Clinical Lipidology 11:4, pages 986-997.
Crossref
Crossref
Sandipan Bhattacharjee, Lisa Goldstone, Queeny Ip & Terri Warholak. (2017) Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United States. Multiple Sclerosis International 2017, pages 1-9.
Crossref
Crossref
Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler & Michael Hecker. (2016) Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy. BMC Neurology 16:1.
Crossref
Crossref
Donald A. Barone, Barry A. Singer, Lubo Merkov, Mark Rametta & Gustavo Suarez. (2016) Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors. Neurology and Therapy 5:2, pages 155-167.
Crossref
Crossref
Caroline Vieira Spessotto, Hanaie Cavalli, Audred Cristina Biondo Eboni, Rafael Berlezi Machado, Analara Munardi Mousquer, Lara Both Palazzo, Alessandro Finkelsztejn, Marcus Vinicius Magno Goncalves, Henry Koiti Sato, Fabio Siquineli & Yara Dadalti Fragoso. (2016) Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis. Arquivos de Neuro-Psiquiatria 74:8, pages 617-620.
Crossref
Crossref
Dennis BourdetteFrancesco Patti. (2016) US health insurance is an obstacle to disease-modifying treatments in MS. Neurology 87:4, pages 346-347.
Crossref
Crossref
Daniel Golan, Elsebeth Staun-Ram & Ariel Miller. (2016) Shifting paradigms in multiple sclerosis. Current Opinion in Neurology 29:3, pages 354-361.
Crossref
Crossref
Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Jörg Czekalla, Klaus Hechenbichler, Volker Limmroth & Michael Hecker. (2016) Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary. Advances in Therapy 33:5, pages 834-847.
Crossref
Crossref
Tjalf Ziemssen, Lauren Sylvester, Mark Rametta & Amy Perrin Ross. (2015) Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™). Neurology and Therapy 4:2, pages 125-136.
Crossref
Crossref
A. Bertolotto, L. Granieri, F. Marnetto, P. Valentino, A. Sala, M. Capobianco, S. Malucchi, A. Di Sapio, M. Malentacchi, M. Matta & M. Caldano. (2015) Biological monitoring of IFN-β therapy in Multiple Sclerosis. Cytokine & Growth Factor Reviews 26:2, pages 241-248.
Crossref
Crossref
Alberto Gajofatto & Maria Donata Benedetti. (2015) Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?. World Journal of Clinical Cases 3:7, pages 545.
Crossref
Crossref